Cost-effectiveness analysis of benmelstobart, anlotinib, and chemotherapy in extensive-stage small-cell lung cancer

Cost-effectiveness analysis of benmelstobart, anlotinib, and chemotherapy in extensive-stage small-cell lung cancer

BackgroundThe ETER701 trial assessed the efficacy and safety of benmelstobart combined with anlotinib plus etoposide/cisplatin (BEN-AL-EC) as a first-line therapy for extensive-stage small-cell lung cancer (ES-SCLC). Results indicated that BEN-AL-EC, when compared with placebo in combination with et...

Full description

Saved in:
Bibliographic Details
Main Authors: Maojin You, Lingling Luo, Tingting Lu, Shaofang Chen, Ying He
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-11-01
Series:Frontiers in Immunology
Subjects:
cost-effectiveness
benmelstobart
anlotinib
chemotherapy
first-line treatment
extensive-stage small-cell lung cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1477146/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items